Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
FDA sets January action date for Keytruda in early bladder cancerMerck & Co/MSD has filed for approval of its PD-1 inhibitor Keytruda in a hard-to-treat form of bladder Share XFDA sets January action date for Keytruda in early bladder cancerhttps://pharmaphorum.com/news/fda-sets-january-action-date-for-keytruda-in-early-bladder-cancer/
The best-selling drugs of the next 5 yearsMerck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling drug by annual revenue in Share XThe best-selling drugs of the next 5 yearshttps://pharmaphorum.com/views-analysis-sales-marketing/the-best-selling-drugs-of-the-next-5-years/
Merck, Eisai get triple approvals for Keytruda/Lenvima combinationThe combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in Share XMerck, Eisai get triple approvals for Keytruda/Lenvima combinationhttps://pharmaphorum.com/news/merck-eisai-get-triple-approvals-for-keytruda-lenvima-combination/
Keytruda combo cleared as first-line kidney cancer treatment in EUMerck & Co/MSD’s Keytruda has added first-line kidney cancer treatment to its ever-lengthening list of approved uses in Share XKeytruda combo cleared as first-line kidney cancer treatment in EUhttps://pharmaphorum.com/news/keytruda-combo-cleared-first-line-kidney-cancer-treatment-eu/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
Study resurrects Merck’s hopes for Keytruda in breast cancerJust a few weeks ago Merck & Co was lamenting a failed trial for Keytruda in triple-negative breast Share XStudy resurrects Merck’s hopes for Keytruda in breast cancerhttps://pharmaphorum.com/news/study-resurrects-mercks-hopes-for-keytruda-in-breast-cancer/
Merck claims a brace of head and neck cancer approvalsMerck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals Share XMerck claims a brace of head and neck cancer approvalshttps://pharmaphorum.com/news/merck-claims-a-brace-of-head-and-neck-cancer-approvals/
SMC approves medicines for breast cancer, skin cancer, schizophreniaThe Scottish Medicines Consortium (SMC) has given approvals to Lilly’s breast cancer drug Verzenios, Merck’s Keytruda and Allergan’s Share XSMC approves medicines for breast cancer, skin cancer, schizophreniahttps://pharmaphorum.com/news/smc-approves-medicines-for-breast-cancer-skin-cancer-schizophrenia/
